Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Findings From the EXTEND-DAPT Study

被引：10
|
作者：
Faridi, Kamil F. [1 ,2 ]
Tamez, Hector [2 ]
Strom, Jordan B. [2 ]
Song, Yang [4 ]
Butala, Neel M. [3 ]
Shen, Changyu [2 ]
Secemsky, Eric A. [2 ]
Mauri, Laura [4 ,5 ]
Curtis, Jeptha P. [1 ]
Gibson, C. Michael [2 ,4 ]
Yeh, Robert W. [2 ,3 ,4 ]
机构：
[1] Yale Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT USA
[2] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA 02115 USA
[4] Baim Inst Clin Res, Boston, MA USA
[5] Medtronic, Minneapolis, MN USA
来源：
CIRCULATION | 2020年 / 142卷 / 03期
关键词：
administrative claims; healthcare; clinical trial; coronary artery disease;
D O I：
10.1161/CIRCULATIONAHA.120.047729
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：306 / 308
页数：3
相关论文
共 50 条
  • [31] P2Y12 Inhibitor Monotherapy After a Short Dual Antiplatelet Therapy Versus Standard-Term Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: A Contemporary Meta-Analysis
    Ho, Ai-Chen
    Egolum, Ugochukwu
    Parker, Shanea
    Dimmel, Jordan
    Hawkins, Andrew
    Ling, Hua
    CLINICAL DRUG INVESTIGATION, 2020, 40 (09) : 799 - 808
  • [32] Stroke rate after twelve versus 30 month dual antiplatelet therapy in percutaneous coronary intervention patients using Korean National Health Insurance Service (NHIS)
    Lee, K. M.
    Kim, M. H.
    Choi, S. Y.
    Kim, S. J.
    Kim, H. B.
    Kang, S. Y.
    Serebruany, V.
    EUROPEAN HEART JOURNAL, 2017, 38 : 836 - 836
  • [33] Sex-Based Outcomes of P2Y12 Inhibitor Monotherapy After Three Months of Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention
    Shin, Eun-Seok
    Her, Ae-Young
    Kim, Bitna
    Hahn, Joo-Yong
    Bin Song, Young
    Lee, Joo Myung
    Park, Taek Kyu
    Yang, Jeong Hoon
    Choi, Jin-Ho
    Choi, Seung-Hyuk
    Lee, Sang Hoon
    Gwon, Hyeon-Cheol
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2023, 38 (45)
  • [34] P2Y12 Inhibitor Monotherapy versus Conventional Dual Antiplatelet Therapy in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Meta-Analysis
    Feng, Wen-Han
    Chang, Yong-Chieh
    Lin, Yi-Hsiung
    Chen, Hsiao-Ling
    Chen, Chun-Yin
    Lin, Tsung-Han
    Lin, Tzu-Chieh
    Chang, Ching-Tang
    Kuo, Hsuan-Fu
    Chang, Hsiu-Mei
    Chu, Chih-Sheng
    PHARMACEUTICALS, 2023, 16 (02)
  • [35] Short Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 1-Year Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
    Joseph, Meghna
    Krishna, Mrinal Murali
    Ezenna, Chidubem
    Pereira, Vinicius
    Franco, Ancy Jenil
    Goldsweig, Andrew
    CIRCULATION, 2024, 150
  • [36] Discontinuation of Dual Antiplatelet Therapy Over 12 Months after Acute Coronary Syndromes Increases Risk for Adverse Events in Patients Treated with Percutaneous Coronary Intervention: Systematic Review and Meta-Analysis
    D'Ascenzo, Fabrizio
    Colombo, Francesco
    Barbero, Umberto
    Moretti, Claudio
    Omede, Pierluigi
    Reed, Matthew J.
    Tarantini, Giuseppe
    Frati, Giacomo
    Di Nicolantonio, James J.
    Zoccai, Giuseppe Biondi
    Gaita, Fiorenzo
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2014, 27 (03) : 233 - 241
  • [37] Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study
    Mehran, Roxana
    Baber, Usman
    Steg, Philippe Gabriel
    Ariti, Cono
    Weisz, Giora
    Witzenbichler, Bernhard
    Henry, Timothy D.
    Kini, Annapoorna S.
    Stuckey, Thomas
    Cohen, David J.
    Berger, Peter B.
    Iakovou, Ioannis
    Dangas, George
    Waksman, Ron
    Antoniucci, David
    Sartori, Samantha
    Krucoff, Mitchell W.
    Hermiller, James B.
    Shawl, Fayaz
    Gibson, C. Michael
    Chieffo, Alaide
    Alu, Maria
    Moliterno, David J.
    Colombo, Antonio
    Pocock, Stuart
    LANCET, 2013, 382 (9906): : 1714 - 1722
  • [38] Abbreviated Versus Standard Dual Antiplatelet Therapy Times After Percutaneous Coronary Intervention in Patients With High Bleeding Risk With Acute Coronary Syndrome: Insights From the SWEDEHEART Registry
    Hakansson, Anton
    Koul, Sasha
    Omerovic, Elmir
    Andersson, Jonas
    James, Stefan
    Agewall, Stefan
    Mokhtari, Arash
    van der Pals, Jesper
    Wester, Axel
    Szummer, Karolina
    Jernberg, Tomas
    Erlinge, David
    Mohammad, Moman A.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (13): : e034709
  • [39] Suvival benefit with 12 versus 6-months dual antiplatelet therapy after coronary stent implantation: a report from BASKET and BASKET-PROVE
    Jeger, R.
    Pfisterer, M.
    Sorensen, R.
    Von Felten, S.
    Alber, H.
    Eberli, F.
    Erne, P.
    Rickli, H.
    Galatius, S.
    Kaiser, C.
    EUROPEAN HEART JOURNAL, 2013, 34 : 354 - 354
  • [40] The Risk/Benefit Tradeoff of Extending Dual Antiplatelet Therapy More than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention
    Wang, Haoyu
    Yin, Dong
    Dou, Kefei
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (14) : S21 - S21
12345